Stockreport

AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP

AIM ImmunoTech Inc.  (AIM) 
PDF Company to participate in Live Virtual Investor Closing Bell segment today, April 16th?at?4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE N [Read more]